Learning disabilities

Regencell Bioscience Holdings Limited Announces Pricing of Approximately $21.9 Million Initial Public Offering

Retrieved on: 
Thursday, July 15, 2021

Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.

Key Points: 
  • Regencell Bioscience Holdings Limited (NASDAQ:RGC) (Regencell or the Company), an early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine (TCM) for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder (ADHD) and Autism Spectrum Disorder (ASD), today announced the pricing of its initial public offering (Offering) of 2,300,000 ordinary shares at a public offering price of $9.50 per ordinary share.
  • Regencell expects to receive aggregate gross proceeds of approximately $21.9 million from this Offering, before deducting underwriting discounts and other related expenses.
  • The Offering is expected to close on or about July 20, 2021, subject to the satisfaction of customary closing conditions.
  • Regencell Bioscience Holdings Limited is an early-stage bioscience company that focuses on research, development and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, specifically ADHD and ASD.

Assisted Living Locators National Team Gears Up For Walk To End Alzheimer's

Retrieved on: 
Thursday, July 15, 2021

PHOENIX, July 15, 2021 /PRNewswire/ -- Assisted Living Locators, a National Team member of the Alzheimer's Association Walk to End Alzheimer's, is gearing up to support the world's largest event dedicated to Alzheimer's care, support and research.

Key Points: 
  • PHOENIX, July 15, 2021 /PRNewswire/ -- Assisted Living Locators, a National Team member of the Alzheimer's Association Walk to End Alzheimer's, is gearing up to support the world's largest event dedicated to Alzheimer's care, support and research.
  • "Assisted Living Locators is proud to support the Alzheimer's Association," said Angela Olea, Assisted Living Locators CEO RN.
  • Carolyn Marengere, Assisted Living Locators Metro Detroit franchisee and National Walk Team Coordinator, says it's exciting to have franchisees nationwide participating this year.
  • To join Assisted Living Locators' Walk to End Alzheimer's team, visit www.alz.org/assistedlivinglocators .If have questions about dementia care, speak to an Assisted Living Locators Senior Care Advisor at 877-266-7788 or visit www.assistedlivinglocators.com .

Cognito Therapeutics Announces Upcoming Data Presentations at the Alzheimer’s Association International Conference 2021

Retrieved on: 
Wednesday, July 14, 2021

Cognito Therapeutics , a clinical-stage company developing a new class of disease-modifying digital therapeutics targeting neuronal pathophysiology to treat neurodegenerative disorders, today announced the acceptance of six research abstracts at the Alzheimers Association International Conference 2021 (AAIC) .

Key Points: 
  • Cognito Therapeutics , a clinical-stage company developing a new class of disease-modifying digital therapeutics targeting neuronal pathophysiology to treat neurodegenerative disorders, today announced the acceptance of six research abstracts at the Alzheimers Association International Conference 2021 (AAIC) .
  • The largest international meeting dedicated to advancing dementia science, AAIC will be held as an online and in-person event in Denver, Colorado, July 26-30, 2021.
  • Our clinical team continues to produce compelling patient data of both physiological and symptomatic improvements that support disease modification for our lead digital therapeutic development program in mild cognitive impairment (MCI) and Alzheimers Disease, said Brent Vaughan, Chief Executive Officer, Cognito Therapeutics.
  • Cognito Therapeutics is a clinical-stage company developing a pipeline of disease-modifying digital therapeutics targeting neurodegenerative disorders.

Ensuring Timely, Appropriate And Equitable Access To Aduhelm

Retrieved on: 
Sunday, July 11, 2021

CHICAGO, July 11, 2021 /PRNewswire/ --Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia.

Key Points: 
  • CHICAGO, July 11, 2021 /PRNewswire/ --Aduhelm has been approved for use for those with Mild Cognitive Impairment or early stage Alzheimer's dementia.
  • Though approved, access to the treatment is at risk of being impeded by significant barriers which may further deepen issues of health equity.
  • From the Association's very first comment on aducanumab, we have stressed the importance of post-approval surveillance through a confirmatory trial.
  • The Alzheimer's Association is committed to working with CMS and the private payer community to expedite access for the appropriate population, which has such significant need.

Alzheimer's Association Welcomes Revised Label For Aduhelm

Retrieved on: 
Thursday, July 8, 2021

CHICAGO, July 8, 2021 /PRNewswire/ --The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm (aducanumab).

Key Points: 
  • CHICAGO, July 8, 2021 /PRNewswire/ --The Alzheimer's Association is pleased with the announcement today that the Food and Drug Administration (FDA) has revised the prescribing label for Aduhelm (aducanumab).
  • "Today's announcement is consistent with the Alzheimer's Association position that Aduhelm should be made available specifically to the population represented in the clinical trials where there was evidence of clinical benefit," said Maria C. Carrillo, Ph.D., Alzheimer's Association chief science officer.
  • The Alzheimer's Association is committed to working with the Centers for Medicare & Medicaid Services (CMS) and the private payer community to expedite access for the appropriate population, which has such significant need.
  • The Alzheimer's Association leads the way to end Alzheimer's and all other dementia by accelerating global research, driving risk reduction and early detection, and maximizing quality care and support.

Belmont Village Senior Living Shares Key Neuroscience Insights into Better Understanding the Alzheimer’s Brain from Yale University’s Dr. Stephen Strittmatter

Retrieved on: 
Thursday, July 8, 2021

Belmont Village Senior Living was honored to sponsor an incredibly rich & important discussion with the brilliant Dr. Strittmatter, says Patricia Will, founder and CEO of Belmont Village.

Key Points: 
  • Belmont Village Senior Living was honored to sponsor an incredibly rich & important discussion with the brilliant Dr. Strittmatter, says Patricia Will, founder and CEO of Belmont Village.
  • At Belmont Village, we know everyone experiences memory loss differently, so learning details of how it occurs is essential to executing proper memory preservation therapy techniques and activities.
  • Dr. Strittmatter mentioned that while there are medications approved to provide slight symptomatic benefit, there is still no cure for Alzheimers.
  • The plaques, and the cells causing the biochemical reaction, are key factors in identifying Alzheimers in the brain.

FDA Approves Updated ADUHELM™ Prescribing Information to Emphasize Population Studied in Clinical Trials

Retrieved on: 
Thursday, July 8, 2021

Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

Key Points: 
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.
  • The update clarifies the indication by emphasizing information about the disease stages studied in the ADUHELM clinical trials.
  • Information about the population studied has been previously communicated by Biogen and Eisai, including in the companies statement of June 23, 2021.
  • Treatment with ADUHELM should be initiated in patients with mild cognitive impairment or mild dementia stage of disease, the population in which treatment was initiated in clinical trials.

SciSparc to Commence Phase IIa Clinical Trial of SCI-110 for the Treatment of Alzheimer's Disease and Agitation

Retrieved on: 
Wednesday, July 7, 2021

Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.

Key Points: 
  • Dr. Adi Zuloff-Shani, PhD, Chief Technologies Officer of SciSparc, commented on the announcement, "We are very excited to begin our trial.
  • Right now, the most common medical treatment for agitation associated with Alzheimer's is off-label use of antipsychotic drugs, which typically provide only marginal improvement, often with undesirable side effects.
  • AD is an irreversible neurodegenerative disease that causes progressive and disabling impairment of cognitive functions including memory, comprehension, language, attention, reasoning and judgment.
  • SciSparc Ltd. is a specialty clinical-stage pharmaceutical company led by an experienced team of senior executives and scientists.

Athira Pharma Announces Initiation of Open Label Extension Study for LIFT-AD and ACT-AD Clinical Trials of ATH-1017 for Alzheimer’s Disease

Retrieved on: 
Tuesday, July 6, 2021

The data we will continue to collect in this open label extension could help us to better understand the long-term safety and efficacy profile of ATH-1017 and could help Athira best design future clinical trials of ATH-1017.

Key Points: 
  • The data we will continue to collect in this open label extension could help us to better understand the long-term safety and efficacy profile of ATH-1017 and could help Athira best design future clinical trials of ATH-1017.
  • The randomized, double-blind, placebo-controlled trials are evaluating the safety and efficacy of ATH-1017 in mild-to-moderate Alzheimers disease.
  • Patients in both trials are being evaluated for improvement in cognition, global and functional assessments comparing treatment arms to placebo.
  • In addition to Alzheimers disease, ATH-1017 is designed to address the broader dementia population, including Parkinsons disease dementia.

Belmont Village Senior Living Shares Six Tips to Mitigate Cognitive Decline Without Meds

Retrieved on: 
Wednesday, June 30, 2021

With an estimated 6.2 million Americans age 65+ living with Alzheimer's disease , many families struggle to slow cognitive decline in loved ones.

Key Points: 
  • With an estimated 6.2 million Americans age 65+ living with Alzheimer's disease , many families struggle to slow cognitive decline in loved ones.
  • Belmont Village Senior Living shares six lifestyle tips that when applied systematically and under the guidance of trained professionals, can help alter cognitive decline.
  • More and more, things are forgotten or misplaced, says Patricia Will, founder & CEO of Belmont Village Senior Living.
  • Each is still a human being with a spirit that must be kept alive, relevant, and hopeful, says Beverly Sanborn, VP of Program Development at Belmont Village Senior Living.